Key Highlights
- Dr. Catherine Bonuccelli joins Scientific Advisory Board.
- Joan Shaw appointed Senior VP, Clinical Operations.
- Taplucainium Phase 2b clinical trial for chronic cough begins late 2024.
- Both Bonuccelli and Shaw instrumental in camlipixant’s development at Bellus Health.
- Taplucainium offers a novel approach for chronic cough treatment.
Source: Business Wire
Notable Quote
- “We are delighted to welcome Cathy and Joan to our scientific/clinical teams as we prepare for the start of our ASPIRE (Phase 2b) clinical trial of Taplucainium in 240 chronic cough patients in the second half of 2024.” — Rick Batycky, CEO at Nocion Therapeutics
SoHC's Take
The strategic appointments of Dr. Catherine Bonuccelli and Joan Shaw underscore Nocion Therapeutics’ commitment to advancing its innovative therapeutic solutions. Both leaders bring a wealth of experience from their tenure at Bellus Health, where they significantly contributed to the development of camlipixant for chronic cough. Their expertise is poised to drive the successful progression of Taplucainium through its upcoming Phase 2b clinical trial. This development highlights Nocion’s robust pipeline and dedication to addressing unmet medical needs in conditions like chronic cough, showcasing the potential of their novel nocion technology to revolutionize treatment paradigms in respiratory care.
